Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

A Community-Led Approach as a Guide to Overcome Challenges for Therapy Research in Congenital Disorders of Glycosylation

View through CrossRef
Congenital Disorders of Glycosylation (CDG) are a large family of rare genetic diseases for which effective therapies are almost nonexistent. To better understand the reasons behind this, to analyze ongoing therapy research and development (R&D) for CDG, and to provide future guidance, a community-led mixed methods approach was organized during the 4th World Conference on CDG for Families and Professionals. In the quantitative phase, electronic surveys pointed to the prioritization of six therapeutic R&D tools, namely biobanks, registries, biomarkers, disease models, natural history studies, and clinical trials. Subsequently, in the qualitative phase, the challenges and solutions associated with these research tools were explored through community-driven think tanks. The multiple challenges and solutions identified administrative/regulatory, communication, financial, technical, and biological issues, which are directly related to three fundamental aspects of therapy R&D, namely data, sample, and patient management. An interdependence was traced between the prioritized tools, with diagnosis and therapies acting as bidirectional triggers that fuel these interrelationships. In conclusion, this study’s pioneering and adaptable community-led methodology identified several CDG therapy R&D gaps, many common to other rare diseases, without easy solutions. However, the strong proactive attitude towards research, based on inclusive and international partnerships and involving all members of the CDG community, sets the direction for better future therapy R&D.
Title: A Community-Led Approach as a Guide to Overcome Challenges for Therapy Research in Congenital Disorders of Glycosylation
Description:
Congenital Disorders of Glycosylation (CDG) are a large family of rare genetic diseases for which effective therapies are almost nonexistent.
To better understand the reasons behind this, to analyze ongoing therapy research and development (R&D) for CDG, and to provide future guidance, a community-led mixed methods approach was organized during the 4th World Conference on CDG for Families and Professionals.
In the quantitative phase, electronic surveys pointed to the prioritization of six therapeutic R&D tools, namely biobanks, registries, biomarkers, disease models, natural history studies, and clinical trials.
Subsequently, in the qualitative phase, the challenges and solutions associated with these research tools were explored through community-driven think tanks.
The multiple challenges and solutions identified administrative/regulatory, communication, financial, technical, and biological issues, which are directly related to three fundamental aspects of therapy R&D, namely data, sample, and patient management.
An interdependence was traced between the prioritized tools, with diagnosis and therapies acting as bidirectional triggers that fuel these interrelationships.
In conclusion, this study’s pioneering and adaptable community-led methodology identified several CDG therapy R&D gaps, many common to other rare diseases, without easy solutions.
However, the strong proactive attitude towards research, based on inclusive and international partnerships and involving all members of the CDG community, sets the direction for better future therapy R&D.

Related Results

Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Objective: To determine the frequency of common chromosomal aberrations in local population idiopathic determine the frequency of common chromosomal aberrations in local population...
DHRSX : revisiting dolichol synthesis
DHRSX : revisiting dolichol synthesis
DHRSX : revisiter la synthèse du dolichol La N-glycosylation est une modification post-traductionnelle essentielle des protéines, se déroulant principalement dans l...
Modulation of ACE2 Glycosylation as a Therapeutic Target for SARS-CoV-2 Infection in Chinese Populations
Modulation of ACE2 Glycosylation as a Therapeutic Target for SARS-CoV-2 Infection in Chinese Populations
Introduction: The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has presented a significant global health challenge. The virus utilizes the angiotensin-converting enzyme 2 (AC...
Implications of aberrant glycosylation on age-related disease progression
Implications of aberrant glycosylation on age-related disease progression
Glycosylation, the enzymatic attachment of glycans to proteins, is a ubiquitous post-translational modification in eukaryotes, responsible for many essential physiological processe...
Innovative Metrics for Reporting and Comparing the Glycan Structural Profile in Biotherapeutics
Innovative Metrics for Reporting and Comparing the Glycan Structural Profile in Biotherapeutics
Glycosylation is a critical quality attribute in biotherapeutics, impacting properties such as protein stability, solubility, clearance rate, efficacy, immunogenicity, and safety. ...
The role of protein glycosylation in Alzheimer disease
The role of protein glycosylation in Alzheimer disease
Glycosylation is one of the most common, and the most complex, forms of post‐translational modification of proteins. This review serves to highlight the role of protein glycosylati...
Effect of C-domain N-glycosylation and deletion on rat pancreaticα-amylase secretion and activity
Effect of C-domain N-glycosylation and deletion on rat pancreaticα-amylase secretion and activity
Even though all animal α-amylases include glycosylation sequons (Asn-Xaa-Thr/Ser) in their sequences, amylases purified from natural sources are not quantitatively glycosylated. Wh...
GENETIC PERSPECTIVE OF THE CONGENITAL HEART DISEASE
GENETIC PERSPECTIVE OF THE CONGENITAL HEART DISEASE
Congenital heart diseases (CHDs) are the structural abnormalities that may occur in the heart, greater veins and arteries or may include the septum between the ventricles and atria...

Back to Top